Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. [electronic resource]
Producer: 20020417Description: 1600-7 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carmustine -- administration & dosage
- Cisplatin -- administration & dosage
- Dacarbazine -- administration & dosage
- Female
- Humans
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Italy
- Male
- Melanoma -- drug therapy
- Middle Aged
- Outpatients
- Proportional Hazards Models
- Prospective Studies
- Quality of Life
- Recombinant Proteins
- Skin Neoplasms -- drug therapy
- Surveys and Questionnaires
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.